The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of POD1UM-201, a phase 2 study of retifanlimab, a humanized anti–PD-1 antibody, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
 
Giovanni Grignani
Honoraria - Bayer; Eisai; Lilly; Merck; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; Lilly; Novartis; Pfizer; PharmaMar
Research Funding - Bayer; Boehringer Ingelheim; Deciphera; Incyte; Novartis; PharmaMar
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Genesis Pharma; Medison; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Celeste Lebbe
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Inflax; Merck Serono; MSD; Novartis; Pierre Fabre; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Other Relationship - BMS; InflaRx; Jazz Pharmaceuticals; MSD; Novartis; Pierre Fabre; Sanofi
 
Michele Guida
Consulting or Advisory Role - Bristol Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre; UCB
Consulting or Advisory Role - Bristol Meyer Squib; Iovance Biotherapeutics; MSD Oncology; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cytovation (Inst); Daiichi Sankyo Europe GmbH (Inst); Day One Biopharmaceuticals (Inst); DOT therapeutics (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); IFX (Inst); Immunocore (Inst); Incyte (Inst); IO Biotech (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Kinnate Biopharma (Inst); Merck (Inst); Microbiotica (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Sairopa (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre
 
Filippo De Braud
Honoraria - BMS; Incyte; Indena; IQVIA; Mattioli 1885; MCCann Health; Menarini; MSD; Pierre Fabre; Taiho Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Pierre Fabre; Sanofi; Taiho Oncology
Speakers' Bureau - Ambrosetti; BMS; Dephaforum; Nadirex International; Novartis
Research Funding - AnHeart Therapeutics; Apollomics; AstraZeneca; BMS
Travel, Accommodations, Expenses - Sanofi
 
Francesco Spagnolo
Honoraria - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Consulting or Advisory Role - MSD; Novartis; Philogen; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Melissa Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Research Funding - Merck
 
Henri Montaudie
Consulting or Advisory Role - BMS; MSD Oncology; Pierre Fabre; Regeneron
Research Funding - BMS (Inst); LEO Pharma (Inst)
Travel, Accommodations, Expenses - BMS; MSD Oncology; MSD Oncology; Pierre Fabre
 
Roberta Depenni
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
 
Francesca Spada
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Novartis
Speakers' Bureau - Advanced Accelerator Applications; Ipsen; Novartis
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Ipsen; Novartis
 
Jennifer Pulini
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Mark Cornfeld
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Chuan Tian
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Shailender Bhatia
Honoraria - Bristol-Myers Squibb; Incyte; Replimune
Consulting or Advisory Role - Bristol Myers Squibb; Incyte; Replimune
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - Regeneron